title: Management of sinonasal undifferentiated carcinoma.
abstract: BACKGROUND
  Our aim was to report the outcomes of treatment for sinonasal undifferentiated carcinoma (SNUC).
  
  
  METHODS
  Between September 1992 and October 2005, 15 patients were treated with curative intent with surgery (n=1), surgery and adjuvant radiotherapy (n=9), and definitive radiotherapy (RT) (n=5). Follow-up ranged from 11 to 151 months (median, 30); follow-up on living patients ranged from 12 to 151 months (median, 22). No patient was lost to follow-up.
  
  
  RESULTS
  Seven patients (47%) developed a recurrence from 3 to 50 months (median, 9) after treatment. The 3-year outcomes were: local control, 78%; locoregional control, 65%; distant metastasis-free survival, 82%; cause-specific survival, 77%, and survival, 67%. The local control rates versus treatment modality were: surgery, 0/1 (0%); surgery and postoperative RT, 7/7 (100%); preoperative RT and surgery, 2/2 (100%); and definitive RT, 2/5 (40%). One patient (7%) treated with surgery and postoperative RT sustained a fatal complication.
  
  
  CONCLUSIONS
  Combined surgery and adjuvant RT likely offer the best chance of cure compared with either modality alone. The impact of adjuvant chemotherapy is unclear.
authors.affiliation: Department of Radiation Oncology, University of Florida, College of Medicine, Gainesville, Florida, USA.
authors.forename: Emily D
authors.initials: ED
authors.lastname: Tanzler
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Morris
authors.forename: Christine A
authors.initials: CA
authors.lastname: Orlando
authors.forename: John W
authors.initials: JW
authors.lastname: Werning
authors.forename: William M
authors.initials: WM
authors.lastname: Mendenhall
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis